Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Placebo-controlled double-blind study in human benign obstructive prostatic hypertrophy with flutamide.

M Bonard, S de Almeida, W von Niederhäusern

    European Urology
    |January 1, 1976
    PubMed
    Summary

    Flutamide, an anti-androgen drug, significantly reduced prostate size in men with benign prostatic hyperplasia. This double placebo-controlled study found no other significant differences compared to placebo.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Total absence of the alpha2(I) chain of collagen type I causes a rare form of Ehlers-Danlos syndrome with hypermobility and propensity to cardiac valvular problems.

    Journal of medical genetics·2006
    Same author

    Long-term follow-up of a family with autosomal dominant polycystic kidney disease type 3.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·1999
    Same author

    Autosomal dominant polycystic kidney disease: evidence for the existence of a third locus in a Portuguese family.

    Human genetics·1995
    Same author

    The EUROGEM map of human chromosome 16.

    European journal of human genetics : EJHG·1994
    Same author

    [Problems in the clinical evaluation of an endoscopic lithotripter. The case of the Lithoclast EMS].

    Annales d'urologie·1994
    Same author

    [Drug addiction: a subject of education for the practitioner?].

    Revue medicale de la Suisse romande·1993

    Area of Science:

    • Urology
    • Pharmacology

    Background:

    • Benign enlargement of the prostate (BPH) affects a significant number of aging men.
    • Non-steroidal anti-androgens are investigated for BPH treatment.
    • Flutamide is a non-steroidal anti-androgen compound.

    Purpose of the Study:

    • To evaluate the efficacy of Flutamide in treating benign enlargement of the prostate.
    • To assess the impact of Flutamide on prostate size and other relevant parameters.

    Main Methods:

    • A double placebo-controlled study design was employed.
    • Thirty-two patients diagnosed with benign enlargement of the prostate participated.
    • Statistical analysis was used to compare Flutamide and placebo groups.

    Main Results:

    Related Experiment Videos

    • A statistically significant reduction in prostate size was observed in the Flutamide group.
    • No significant differences were found between Flutamide and placebo groups in other measured parameters.
    • The study highlights challenges in parameter selection and measurement for BPH investigations.

    Conclusions:

    • Flutamide demonstrates efficacy in reducing prostate size in patients with benign enlargement of the prostate.
    • Further research is needed to explore the full therapeutic potential and optimal use of Flutamide in BPH.
    • Methodological considerations in clinical trials for BPH are important for accurate interpretation of results.